Autologous TLPO Vaccine Basket

PHASE2TerminatedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

July 2, 2025

Study Completion Date

July 2, 2025

Conditions
Tumor, SolidTumor MetastasisCancerTumor
Interventions
BIOLOGICAL

Tumor lysate, particle only (TLPO) vaccine

A novel technology in which a patient's tumor lysate (TL) is loaded into microparticles for DC phagocytosis and antigen processing allows for vaccine efficacy, while minimizing tissue demands by only requiring approximately 250-500ug of tumor. Immature DCs avidly phagocytose small particles in the range of 1-5 microns. Tumor tissue collected from the patient undergoes a process of freeze-thaw cycling to create a TL suspension. The microparticles, yeast-cell wall particles (YCWP), are created from Saccharomyces cerevisiae by NaOH/HCl digestion of all non-cell wall components and washed, producing β-glycan shells. The TL is then loaded into these YCWP.

Trial Locations (1)

29615

Southside Medical Center, Greenville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

LumaBridge

INDUSTRY

lead

Elios Therapeutics, LLC

INDUSTRY

NCT06175221 - Autologous TLPO Vaccine Basket | Biotech Hunter | Biotech Hunter